Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. TA–4-1BBL features a distinct functionality compared to other 4-1BB agonists.
  • Fig. S2. Anti–4-1BB antibodies cross-linked via FcγR induce immune cell accumulation in the liver.
  • Fig. S3. TA–4-1BBL is a flexible molecule with a trimeric 4-1BBL structure.
  • Fig. S4. TA–4-1BBL binds specifically to cell-expressed targets.
  • Fig. S5. In vitro FAP–4-1BBL costimulation improves T cell activation and memory phenotype differentiation.
  • Fig S6. muFAP-4-1BB works in combination with CEA-TCB or anti–PD-L1 in syngeneic mice.
  • Fig S7. CD19–4-1BBL and CD20-TCB combination induces tumor regression also in CD20low-expressing B cell lymphoma.
  • Fig S8. TA–4-1BBL works in cis- and trans-presentation in the presence of signal 1.
  • Table S1. X-ray data collection and refinement statistics for human 4-1BBL–CH1/CL.
  • Table S2. Surface plasmon resonance affinity constants of TA–4-1BBLs.
  • Table S3. FAP–4-1BBL tumor targeting and tissue biodistribution in a CRC-bearing rhesus monkey.
  • Table S4. Monomer content of FAP–4-1BBL in production batches.
  • References (5162)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: